| Bioactivity | Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1]. |
| Invitro | Patritumab deruxtecan 对表达 HER3 突变的乳腺癌细胞表现出活性，无论HER2是否过表达[1]。Patritumab deruxtecan (0-100 nM) 以浓度依赖性方式结合所有 HER3 突变体和 HER3WT MDA-MB-231 细胞的表面，但不结合 HER3EV 细胞[1]. |
| Name | Patritumab deruxtecan |
| CAS | 2227102-46-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Koyama K, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022 May 3;17(5):e0267027. |